ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1545

Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life

Vibeke Strand1, Erin Mangan2, Owen Hagino3, Jonathan Sadeh4, Susan Boklage2 and Toshio Kimura2, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Sanofi, Bridgewater, NJ

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Depression and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The pro-inflammatory cytokine IL-6 has been found to play a critical role in mood disorders, with symptoms such as anxiety and depression having implications for RA disease activity. Studies have shown poorer disease outcomes in RA patients with depression.1 This study evaluated the effect of baseline depressive symptoms on the efficacy of sarilumab and improvements in health-related quality of life (HRQOL).

Methods: Post hoc statistical analyses of clinical and patient-reported outcomes (baseline; Week 24) were conducted in patients with moderately-to-severely active RA from 3 Phase 3 randomized controlled trials (RCTs) comparing the efficacy and safety of subcutaneous (SC) sarilumab 200 mg every 2 weeks (q2w) plus methotrexate (MTX) in MOBILITY [NCT01061736], plus csDMARDs in TARGET [NCT01709578] and as monotherapy versus adalimumab SC 40 mg q2w in MONARCH [NCT02332590].  Patients were categorized with probable Major Depressive Disorder (PMDD)2 at baseline defined by a Mental Health (MH) domain score ≤56 on the Medical Outcomes Study 36-item short form (SF-36) questionnaire.

Results: Of 1197, 546 and 369 patients in MOBILITY, TARGET and MONARCH, respectively, 60.2%, 59.5% and 67.8%, were classified as PMDD. Disease duration, baseline DAS-28 CRP, tender and swollen joint counts and SF-36 MH scores were similar between sarilumab 200mg plus MTX in MOBILITY and sarilumab 200mg plus csDMARDs in TARGET versus placebo, and versus adalimumab in MONARCH in the PMDD subgroups. Interaction between PMDD and non-PMDD subgroups was non-significant for all endpoints except change from baseline in Patient Global Assessment of disease activity in MOBILITY (nominal P < 0.05). Odds ratios for responses by ACR20/50/70, SDAI ≤ 11 and CDAI ≤ 10 at Week 24 were nominally higher with sarilumab 200mg versus placebo in both PMDD and non-PMDD subgroups in MOBILITY (nominal P < 0.0001), TARGET (nominal P < 0.01), and in PMDD by ACR20/50/70 in MONARCH (nominal P < 0.05) (Figure 1). MH scores for PMDD subgroups were nominally higher (P < 0.05) in ACR20 responders with sarilumab 200mg versus placebo at Week 24 in MOBILITY (Figure 2). Sarilumab safety was consistent with IL-6R blockade.

Conclusion: These post-hoc analyses suggest that sarilumab treatment is equally efficacious irrespective of baseline PMDD status.

1. Matcham F et al. BMC Musculoskeletal Disorders. 2016;17:155.

2. Matcham F et al. BMC Musculoskeletal Disorders. 2016;17:224.


Disclosure: V. Strand, Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, 5; E. Mangan, Regeneron Pharmaceuticals Inc., 1, 3; O. Hagino, Sanofi Genzyme, 1, 3; J. Sadeh, Sanofi, 1, 3; S. Boklage, Regeneron Pharmaceuticals, Inc., 1, 3; T. Kimura, Regeneron Pharmaceuticals Inc., 1, 3.

To cite this abstract in AMA style:

Strand V, Mangan E, Hagino O, Sadeh J, Boklage S, Kimura T. Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/exploring-the-effects-of-depressive-symptoms-on-the-efficacy-of-sarilumab-and-improvements-in-health-related-quality-of-life/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-the-effects-of-depressive-symptoms-on-the-efficacy-of-sarilumab-and-improvements-in-health-related-quality-of-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology